title: Mesothelin-targeted agents in clinical trials and in preclinical development.
abstract: Mesothelin is a tumor differentiation antigen that is highly expressed in several malignant diseases in humans, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. The limited expression of mesothelin on normal human tissues and its high expression in many common cancers make it an attractive candidate for cancer therapy. Several agents, including an immunotoxin, monoclonal antibody, antibody drug conjugate, and tumor vaccine, are in various stages of development to treat patients with mesothelin-expressing tumors. This review highlights ongoing clinical trials, as well as other approaches to exploit mesothelin for cancer therapy, that are in preclinical development.
authors.affiliation: Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Ronan J
authors.initials: RJ
authors.lastname: Kelly
authors.forename: Elad
authors.initials: E
authors.lastname: Sharon
authors.forename: Ira
authors.initials: I
authors.lastname: Pastan
authors.forename: Raffit
authors.initials: R
authors.lastname: Hassan
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D058851:GPI-Linked Proteins / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D000090204:Mesothelin; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D058851:GPI-Linked Proteins; D000922:Immunotoxins; D000090204:Mesothelin